Research Article Cites Viraffinity™ in Study of Viral Encephalitis

MONMOUTH JUNCTION, N.J. - Sept. 14, 2022 - PRLog -- Biotech Support Group reports on a new research article describing the simplicity and efficiency of their virus enrichment technology for Sindbis virus (SINV) expressed in cell culture. The citation is:

Yeh, Jane X., et al. "Treatment of Sindbis Virus-Infected Neurons with Antibody to E2 Alters Synthesis of Complete and nsP1-Expressing Defective Viral RNAs (https://journals.asm.org/doi/pdf/10.1128/mbio.02221-22)." Mbio (2022): e02221-22.

Alphaviruses are important causes of viral encephalomyelitis without approved treatments or vaccines. Antibody to the Sindbis virus (SINV) E2 glycoprotein is required for immune-mediated noncytolytic virus clearance from neurons. The investigation used direct RNA nanopore sequencing to evaluate how anti-E2 antibody affects SINV replication at the RNA level. The article states "Extracellular virus particles were isolated from cell culture supernatant fluids … using the Viraffinity virus and viral component isolation kit (BSG). For Viraffinity, virus-containing medium was added at a 4:1 ratio to the water-insoluble elastomeric polyelectrolyte and then microcentrifuged. (Viraffinity™-enriched) Virus pellets were directly lysed with TRIzol reagent….".  The study concludes that antibody-treated neurons released a lower proportion of SINV particles with capped genomes necessary for translation and infection.

"This report demonstrates that Viraffinity™ can substitute for the gold-standard of enrichment using gradient ultracentrifugation. However, the Viraffinity™ method is so simple, it can be applied using a conventional microfuge, and the viral nucleic acids can be directly isolated from the viral pellet. I am very pleased that by using Viraffinity™, the research was able to better understand virus clearance from neurons." states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information visit: Viraffinity™, at
http://www.biotechsupportgroup.com/Viraffinity-Virus-and-Viral-Component-Isolation-p/v1062.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for expanding proteomic analysis. Following a tiered business strategy, the company continues its growth in the consumable research products area. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite™ for lipid adsorption, and HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

For business development contact: Matthew Kuruc
732-274-2866 mkuruc@biotechsupportgroup.com (mailto:sales@biotechsupportgroup.com)

Keywords: alphavirus, defective viral genomes, Viraffinity, neuron viral infection, viral encephalitis, virus enrichment, virus purification